# Heart Failure Treatment and Management

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/heart-failure-treatment-and-management/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, treatment, and management of heart failure, including guidelines, epidemiology, B-type natriuretic peptide testing, cardiovascular disease burden, hospital readmission rates, risk prediction models, and the impact of renal function on outcomes. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10198 |
| Works | 1,202 |

## Topic papers all

Showing 15 of 1202.

- [Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.](https://scholariq.org/papers/corrigendum-to-2021-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and/)
- [2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure](https://scholariq.org/papers/2021-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart/)
- [2013 ACCF/AHA Guideline for the Management of Heart Failure](https://scholariq.org/papers/2013-accf-aha-guideline-for-the-management-of-heart-failure/)
- [Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?](https://scholariq.org/papers/should-we-stop-angiotensin-converting-enzyme-inhibitors-angiotensin-receptor/)
- [K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification](https://scholariq.org/papers/k-doqi-clinical-practice-guidelines-for-chronic-kidney-disease-evaluation/)
- [The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure](https://scholariq.org/papers/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe/)
- [Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/liraglutide-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-2/)
- [Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-versus-enalapril-in-heart-failure/)
- [Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction](https://scholariq.org/papers/effect-of-captopril-on-mortality-and-morbidity-in-patients-with-left-ventricular/)
- [2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure](https://scholariq.org/papers/2016-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-2/)
- [Measurement of health status](https://scholariq.org/papers/measurement-of-health-status/)
- [Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction](https://scholariq.org/papers/eplerenone-a-selective-aldosterone-blocker-in-patients-with-left-ventricular/)
- [The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure](https://scholariq.org/papers/the-effect-of-carvedilol-on-morbidity-and-mortality-in-patients-with-chronic/)
- [Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/trends-in-prevalence-and-outcome-of-heart-failure-with-preserved-ejection/)

## Topic primary papers

Showing 15 of 548.

- [Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.](https://scholariq.org/papers/corrigendum-to-2021-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and/)
- [2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure](https://scholariq.org/papers/2021-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart/)
- [2013 ACCF/AHA Guideline for the Management of Heart Failure](https://scholariq.org/papers/2013-accf-aha-guideline-for-the-management-of-heart-failure/)
- [Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-versus-enalapril-in-heart-failure/)
- [Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction](https://scholariq.org/papers/effect-of-captopril-on-mortality-and-morbidity-in-patients-with-left-ventricular/)
- [The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure](https://scholariq.org/papers/the-effect-of-carvedilol-on-morbidity-and-mortality-in-patients-with-chronic/)
- [Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/trends-in-prevalence-and-outcome-of-heart-failure-with-preserved-ejection/)
- [Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)](https://scholariq.org/papers/effects-of-enalapril-on-mortality-in-severe-congestive-heart-failure-results-of/)
- [2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults](https://scholariq.org/papers/2009-focused-update-incorporated-into-the-acc-aha-2005-guidelines-for-the/)
- [ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008](https://scholariq.org/papers/esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-3/)
- [2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure](https://scholariq.org/papers/2017-acc-aha-hfsa-focused-update-of-the-2013-accf-aha-guideline-for-the-2/)
- [Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure](https://scholariq.org/papers/rapid-measurement-of-b-type-natriuretic-peptide-in-the-emergency-diagnosis-of/)
- [2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary](https://scholariq.org/papers/2013-accf-aha-guideline-for-the-management-of-heart-failure-executive-summary/)
- [Global burden of heart failure: a comprehensive and updated review of epidemiology](https://scholariq.org/papers/global-burden-of-heart-failure-a-comprehensive-and-updated-review-of/)
- [2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America](https://scholariq.org/papers/2017-acc-aha-hfsa-focused-update-of-the-2013-accf-aha-guideline-for-the-3/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.